138 related articles for article (PubMed ID: 20683281)
1. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
Avery RK; Mossad SB; Poggio E; Lard M; Budev M; Bolwell B; Waldman WJ; Braun W; Mawhorter SD; Fatica R; Krishnamurthi V; Young JB; Shrestha R; Stephany B; Lurain N; Yen-Lieberman B
Transplantation; 2010 Aug; 90(4):419-26. PubMed ID: 20683281
[TBL] [Abstract][Full Text] [Related]
2. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
[TBL] [Abstract][Full Text] [Related]
3. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
4. A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
John GT; Manivannan J; Chandy S; Peter S; Fleming DH; Chandy SJ; Balakrishnan N; Krishnamurthy K; Kirubakaran MG; Jacob CK
Transplant Proc; 2005 Dec; 37(10):4303-5. PubMed ID: 16387103
[TBL] [Abstract][Full Text] [Related]
5. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
6. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis.
Reischig T; Jindra P; Hes O; Bouda M; Kormunda S; Treska V
Transplantation; 2009 Feb; 87(3):436-44. PubMed ID: 19202451
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide.
Ehlert K; Groll AH; Kuehn J; Vormoor J
Klin Padiatr; 2006; 218(3):180-4. PubMed ID: 16688677
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Verkaik NJ; Hoek RA; van Bergeijk H; van Hal PT; Schipper ME; Pas SD; Beersma MF; Boucher CA; Jedema I; Falkenburg F; Hoogsteden HC; van den Blink B; Murk JL
Transpl Infect Dis; 2013 Dec; 15(6):E243-9. PubMed ID: 24298985
[TBL] [Abstract][Full Text] [Related]
10. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
11. [Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
Gómez Valbuena I; Alioto D; Serrano Garrote O; Ferrari Piquero JM
Farm Hosp; 2016 Jan; 40(1):52-4. PubMed ID: 26882834
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease.
Humar A; Kumar D; Boivin G; Caliendo AM
J Infect Dis; 2002 Sep; 186(6):829-33. PubMed ID: 12198618
[TBL] [Abstract][Full Text] [Related]
14. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide for cytomegalovirus: bench to bedside.
Chacko B; John GT
Transpl Infect Dis; 2012 Apr; 14(2):111-20. PubMed ID: 22093814
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus after heart transplantation: definitions for the guidance of antiviral therapy.
Iberer F; Tscheliessnigg K; Halwachs G; Auer T; Wasler A; Petutschnigg B; Schreier G; Müller H; Allmayer T; Prenner G
Scand J Infect Dis Suppl; 1995; 99():100-3. PubMed ID: 8668929
[TBL] [Abstract][Full Text] [Related]
18. A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients.
Madan RP; Campbell AL; Shust GF; Kahn AR; Wistinghausen B; Posada R; Kerkar N; Shneider BL; Emre S; Herold BC
Transplantation; 2009 May; 87(9):1318-24. PubMed ID: 19424031
[TBL] [Abstract][Full Text] [Related]
19. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
Loginov R; Höckerstedt K; Lautenschlager I
Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
[TBL] [Abstract][Full Text] [Related]
20. Utility of Leflunomide in the Treatment of Drug Resistant Cytomegalovirus Retinitis.
Rifkin LM; Minkus CL; Pursell K; Jumroendararasame C; Goldstein DA
Ocul Immunol Inflamm; 2017 Feb; 25(1):93-96. PubMed ID: 26652481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]